Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
UTRECHT, The Netherlands, Jan. 02, 2018 -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:30 a.m. PT.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is expected to soon be evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target and is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus’ website, www.merus.nl.
Contacts:
Investors:
Kimberly Minarovich
+1 646 368 8014
[email protected]
Media:
Eliza Schleifstein
+1 973 361 1546
[email protected]
